Cargando…
Preoperative dexamethasone administration in hepatectomy of 25-min intermittent Pringle’s maneuver for hepatocellular carcinoma: a randomized controlled trial
BACKGROUND: A previous randomized controlled trial demonstrated that intermittent Pringle’s maneuver (IPM) with a 25-min ischemic interval could be applied safely and efficiently in hepatectomy for patients with hepatocellular carcinoma (HCC). But prolonging the hepatic inflow clamping time will ine...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10651268/ https://www.ncbi.nlm.nih.gov/pubmed/37526089 http://dx.doi.org/10.1097/JS9.0000000000000622 |
_version_ | 1785147616378486784 |
---|---|
author | Huang, Yang Xu, Liangliang Wang, Ning Wei, Yonggang Wang, Wentao Xu, Mingqing Jiang, Li |
author_facet | Huang, Yang Xu, Liangliang Wang, Ning Wei, Yonggang Wang, Wentao Xu, Mingqing Jiang, Li |
author_sort | Huang, Yang |
collection | PubMed |
description | BACKGROUND: A previous randomized controlled trial demonstrated that intermittent Pringle’s maneuver (IPM) with a 25-min ischemic interval could be applied safely and efficiently in hepatectomy for patients with hepatocellular carcinoma (HCC). But prolonging the hepatic inflow clamping time will inevitably aggravate the ischemia-reperfusion injury. Therefore, we aimed to evaluate the effect of prophylactic dexamethasone on alleviating surgical stress for HCC patients with a 25-min ischemic interval. METHODS: From December 2022 to April 2023, patients who met the inclusion criteria were randomly assigned to the dexamethasone group or control group. Perioperative data and short-term survival outcomes between the two groups were recorded and compared, and subgroup analysis was performed. RESULTS: Two hundred and seventy patients were allocated to the dexamethasone group (n=135) and control group (n=135). Patients in the dexamethasone group had lower area under the curve of serial alanine aminotransferase (AUC(ALT)) (P=0.043) and aspartate aminotransferase (AUC(AST)) (P=0.009), total bilirubin (TB) (P=0.018), procalcitonin (PCT) (P=0.012), interleukin-6 (IL-6) (P=0.006), incidence of major complication (P=0.031) and shorter postoperative hospital stay (P=0.046) than those in the control group. Subgroup analysis showed that the dexamethasone group experienced milder hepatocellular injury than the control group for patients with cirrhosis, and for patients without cirrhosis, the dexamethasone group experienced milder inflammatory response. Moreover, the dexamethasone group preserved better liver function and experienced milder inflammatory response for patients undergoing major hepatectomy, although the hepatocellular injury was not significantly improved. CONCLUSION: Preoperative dexamethasone administration can help improve perioperative outcomes for HCC patients when applying IPM with a 25-min ischemic interval in hepatectomy. |
format | Online Article Text |
id | pubmed-10651268 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Lippincott Williams & Wilkins |
record_format | MEDLINE/PubMed |
spelling | pubmed-106512682023-11-15 Preoperative dexamethasone administration in hepatectomy of 25-min intermittent Pringle’s maneuver for hepatocellular carcinoma: a randomized controlled trial Huang, Yang Xu, Liangliang Wang, Ning Wei, Yonggang Wang, Wentao Xu, Mingqing Jiang, Li Int J Surg Original Research BACKGROUND: A previous randomized controlled trial demonstrated that intermittent Pringle’s maneuver (IPM) with a 25-min ischemic interval could be applied safely and efficiently in hepatectomy for patients with hepatocellular carcinoma (HCC). But prolonging the hepatic inflow clamping time will inevitably aggravate the ischemia-reperfusion injury. Therefore, we aimed to evaluate the effect of prophylactic dexamethasone on alleviating surgical stress for HCC patients with a 25-min ischemic interval. METHODS: From December 2022 to April 2023, patients who met the inclusion criteria were randomly assigned to the dexamethasone group or control group. Perioperative data and short-term survival outcomes between the two groups were recorded and compared, and subgroup analysis was performed. RESULTS: Two hundred and seventy patients were allocated to the dexamethasone group (n=135) and control group (n=135). Patients in the dexamethasone group had lower area under the curve of serial alanine aminotransferase (AUC(ALT)) (P=0.043) and aspartate aminotransferase (AUC(AST)) (P=0.009), total bilirubin (TB) (P=0.018), procalcitonin (PCT) (P=0.012), interleukin-6 (IL-6) (P=0.006), incidence of major complication (P=0.031) and shorter postoperative hospital stay (P=0.046) than those in the control group. Subgroup analysis showed that the dexamethasone group experienced milder hepatocellular injury than the control group for patients with cirrhosis, and for patients without cirrhosis, the dexamethasone group experienced milder inflammatory response. Moreover, the dexamethasone group preserved better liver function and experienced milder inflammatory response for patients undergoing major hepatectomy, although the hepatocellular injury was not significantly improved. CONCLUSION: Preoperative dexamethasone administration can help improve perioperative outcomes for HCC patients when applying IPM with a 25-min ischemic interval in hepatectomy. Lippincott Williams & Wilkins 2023-07-31 /pmc/articles/PMC10651268/ /pubmed/37526089 http://dx.doi.org/10.1097/JS9.0000000000000622 Text en Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-sa/4.0/This is an open access article distributed under the Creative Commons Attribution-ShareAlike License 4.0 (https://creativecommons.org/licenses/by-sa/4.0/) , which allows others to remix, tweak, and build upon the work, even for commercial purposes, as long as the author is credited and the new creations are licensed under the identical terms. http://creativecommons.org/licenses/by-sa/4.0/ (https://creativecommons.org/licenses/by-sa/4.0/) |
spellingShingle | Original Research Huang, Yang Xu, Liangliang Wang, Ning Wei, Yonggang Wang, Wentao Xu, Mingqing Jiang, Li Preoperative dexamethasone administration in hepatectomy of 25-min intermittent Pringle’s maneuver for hepatocellular carcinoma: a randomized controlled trial |
title | Preoperative dexamethasone administration in hepatectomy of 25-min intermittent Pringle’s maneuver for hepatocellular carcinoma: a randomized controlled trial |
title_full | Preoperative dexamethasone administration in hepatectomy of 25-min intermittent Pringle’s maneuver for hepatocellular carcinoma: a randomized controlled trial |
title_fullStr | Preoperative dexamethasone administration in hepatectomy of 25-min intermittent Pringle’s maneuver for hepatocellular carcinoma: a randomized controlled trial |
title_full_unstemmed | Preoperative dexamethasone administration in hepatectomy of 25-min intermittent Pringle’s maneuver for hepatocellular carcinoma: a randomized controlled trial |
title_short | Preoperative dexamethasone administration in hepatectomy of 25-min intermittent Pringle’s maneuver for hepatocellular carcinoma: a randomized controlled trial |
title_sort | preoperative dexamethasone administration in hepatectomy of 25-min intermittent pringle’s maneuver for hepatocellular carcinoma: a randomized controlled trial |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10651268/ https://www.ncbi.nlm.nih.gov/pubmed/37526089 http://dx.doi.org/10.1097/JS9.0000000000000622 |
work_keys_str_mv | AT huangyang preoperativedexamethasoneadministrationinhepatectomyof25minintermittentpringlesmaneuverforhepatocellularcarcinomaarandomizedcontrolledtrial AT xuliangliang preoperativedexamethasoneadministrationinhepatectomyof25minintermittentpringlesmaneuverforhepatocellularcarcinomaarandomizedcontrolledtrial AT wangning preoperativedexamethasoneadministrationinhepatectomyof25minintermittentpringlesmaneuverforhepatocellularcarcinomaarandomizedcontrolledtrial AT weiyonggang preoperativedexamethasoneadministrationinhepatectomyof25minintermittentpringlesmaneuverforhepatocellularcarcinomaarandomizedcontrolledtrial AT wangwentao preoperativedexamethasoneadministrationinhepatectomyof25minintermittentpringlesmaneuverforhepatocellularcarcinomaarandomizedcontrolledtrial AT xumingqing preoperativedexamethasoneadministrationinhepatectomyof25minintermittentpringlesmaneuverforhepatocellularcarcinomaarandomizedcontrolledtrial AT jiangli preoperativedexamethasoneadministrationinhepatectomyof25minintermittentpringlesmaneuverforhepatocellularcarcinomaarandomizedcontrolledtrial |